Tier 2 — strong

Berberine is a novel cholesterol-lowering drug working through a unique mechanism distinct from statins

Kong W, Wei J, Abidi P, Lin M, Inaba S, Li C, Wang Y, Wang Z, Si S, Pan H, Wang S, Wu J, Wang Y, Li Z, Liu J, Jiang JD
Nature medicine 2004 10(12):1344-1351

Bibliography

PubMed
PMID 15531889
DOI
10.1038/nm1135
Funding
Indexed support: NCI NIH HHS. See the publication for grant details.
Competing interests
A complete competing-interest declaration was not available in the accessible source; no absence of conflicts is inferred.

Study snapshot

DesignHuman intervention with separate preclinical experiments
ModelHuman participants; see population
Sample32 hypercholesterolemic patients; separate hamster/cell experiments
InterventionOral berberine; LDL-receptor experiments in animals and cells
Duration3 months in humans
EndpointsTotal and LDL cholesterol; Triglycerides and apolipoproteins; Metabolic and vascular biomarkers

What the study showed, in plain terms

This foundational report links lower human cholesterol with laboratory evidence of LDL-receptor regulation. The mechanistic component supports plausibility, while the small human component has limited causal certainty.

Key findings

  • Reported human changes included LDL cholesterol about 25% lower than baseline.
  • Laboratory work implicated stabilization of LDL-receptor messenger RNA.

What this study can and cannot tell us

The human study is small; hamster and cell results do not establish prevention of heart attacks.

Source detail: indexed abstract and bibliographic record; unavailable methods or disclosures are identified rather than assumed.

Related papers in the corpus

Tier 2
Sex-Specific Lipid, Apolipoprotein B, and Lipoprotein(a) Responses to Berberine Based on 2 Randomized Placebo-Controlled Trials
Zhao JV et al. · JACC. Asia · 2026
Tier 2
Effect of Berberine on Cardiovascular Disease Risk Factors: A Mechanistic Randomized Controlled Trial
Zhao JV et al. · Nutrients · 2021
Tier 2
Effect of Berberine Plus Bezafibrate Administration on the Lipid Profile of Patients with Mixed Dyslipidemia: A Pilot Clinical Trial
León-Martínez JM et al. · Journal of medicinal food · 2021
Tier 2
Effects of a New Nutraceutical Formulation (Berberine, Red Yeast Rice and Chitosan) on Non-HDL Cholesterol Levels in Individuals with Dyslipidemia: Results from a Randomized, Double Blind, Placebo-Controlled Study
Spigoni V et al. · International journal of molecular sciences · 2017
Tier 2
[Therapeutic Effects of Berberine Capsule on Patients with Mild Hyperlipidemia]
Wang L et al. · Zhongguo Zhong xi yi jie he za zhi Zhongguo Zhongxiyi jiehe zazhi = Chinese journal of integrated traditional and Western medicine · 2016

Citation network

Articles citing this research paper

2 articles

Biohack Blueprint analyses that reference this study in their evidence base.

Editorial review

Reviewed by the Biohack Blueprint research team

Last verified

Dr. Khaled Mahmoud, MBBChCritical Care Medicine, Longevity Science & Editorial Direction Dr. Amr Yasser, PhDCardiometabolic, Musculoskeletal, Gut & Bioavailability Dr. Abdulla Mostafa, PhDCellular Senescence, Neurological, Mitochondrial & Brain-Ageing Biology